In the wake of the company disclosing in May that it would be delaying its Biologic License Application filing with the FDA for its key drug until the first half of 2022, the biotech stock discussed in today’s article is down over 50% from its January highs. Ark Invest’s Cathie Wood took the sell-off as a buying opportunity and picked up an additional 1 million shares. Given that Wood has proven her prowess as a stock-picker, is this biotech stock a buy? CLICK HERE.
Is The Sell-Off In This Biotech Stock A Buying Opportunity? Cathie Wood Thinks So.
- by RobH